Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025.
Patton ME, Moline HL, Whitaker M, Tannis A, Pham H, Toepfer AP, Taylor CA, Goldstein L, Reingold A, Kirley PD, Alden NB, Kawasaki B, Meek J, Kim D, Witt LS, Openo KP, Ryan PA, Mumm E, Lynfield R, Salazar-Sanchez Y, Pacheco F, Keating F, Anderson BJ, Tesini BL, Felsen CB, Sutton M, Thomas A, Schaffner W, Talbot HK, Harbi K, Doran E, Weinberg GA, Staat MA, Payne DC, Halasa NB, Stewart L, Boom JA, Sahni LC, Klein EJ, Englund JA, Williams JV, Michaels MG, Schuster JE, Selvarangan R, Szilagyi PG, Havers FP, Dawood FS.
Patton ME, et al. Among authors: taylor ca.
MMWR Morb Mortal Wkly Rep. 2025 May 8;74(16):273-281. doi: 10.15585/mmwr.mm7416a1.
MMWR Morb Mortal Wkly Rep. 2025.
PMID: 40338822
Free PMC article.